CANCER RESEARCH AND TREATMENT (CRT)
Original Article Prognostic Factors for Risk Stratification of Patients Recurrent or Metastatic Pancreatic Adenocarcinoma Who were Treated with Gemcitabine-Based Chemotherapy Inkeun Park, MD1, Seung Joon Choi, MD, PhD2, Young Saing Kim, MD1, Hee Kyung Ahn,
le
MD1, Junshik Hong, MD1, Sun Jin Sym, MD, PhD1, Jinny Park, MD, PhD1, Eun Kyung Cho,
tic
MD, PhD1, Jae Hoon Lee, MD, PhD1, Yong Ju Shin, BSPH3, Dong Bok Shin, MD, PhD1
1
Ar
*Inkeun Park and Seung Joon Choi contributed equally to this work.
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University
Gil Medical Center, Incheon, 2Department of Radiology, Gachon University Gil Medical 3
Department of Preventive Medicine, Gachon University College of
Medicine, Incheon, Korea
ed
Center, Incheon,
pt
Running title: Sarcopenia in recurrent or metastatic pancreatic cancer
ce
Correspondence: Dong Bok Shin, MD, PhD Division of Hematology and Oncology, Department of Internal Medicine, Gachon University
Ac
Gil Medical Center, 21 Namdong-daero 774 beon-gil, Namdong-gu, Incheon 21565, Korea Tel: 82-32-460-8371
Fax: 82-32-460-2391
E-mail:
[email protected]
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an ‘Accepted Article’, doi:10.4143/crt.2015.250
1 Korean Cancer Association This article is protected by copyright. All rights reserved.
CANCER RESEARCH AND TREATMENT (CRT)
Abstract Purpose The aim of this study was to verify prognostic factors including sarcopenia in patients with recurrent or metastatic pancreatic cancer receiving gemcitabine based chemotherapy. Materials and Methods
le
Medical records and computed tomography scan of consecutive patients treated with palliative gemcitabine based chemotherapy from 2008 to 2014 were reviewed. The lumbar
tic
skeletal muscle index at 3rd lumbar spine level was computed, and together with clinicolaboratory factors, univariate and multivariable analyses for overall survival (OS) were performed.
Ar
Results
A total of 88 patients were found. Median age was 65 years, and male patients were predominant (67.0%). Most patients had initially metastatic disease (72.7%), and gemcitabine
ed
monotherapy was administered in 29 patients (33.0%) while gemcitabine plus erlotinib was administered in 59 patients (67.0%). Seventy six patients (86.3%) had sarcopenia. With a median follow-up period of 44.32 months (range 0.6-44.3 months), median OS was 5.35
pt
months (95% CI 4.11-6.59 months). In univariate and multivariable analysis, high carcinoembryonic antigen level [hazard ratio (HR) 4.18, 95% CI 1.95-8.97, p 50%)
ed
of the bootstrap models, the original final stepwise regression model can be judged as stable. Statistical analyses were performed using SPSS software for Windows version 18.0 (SPSS
pt
Inc., Chicago, IL) and SAS version 9.3 (SAS Institute, Cary, NC), and p
